Why Partner with Akoya Biosciences?
As inventors of the Phenoptics™ technology, we leverage deep expertise in multiplex immunofluorescence and cutting-edge spatial technologies to design and develop your next-generation spatial biomarker assays.
Akoya’s Advanced Biopharma Solutions (ABS) is a premium service for biopharmaceutical companies who want to discover and develop actionable spatial biomarkers for their translational pathology and immunotherapy programs.
Custom Assay Development
Fit-for-purpose analytically validated panels to support RUO projects, trial enrollment, and clinical studies.
Proprietary Image Analysis
Advanced tools and technical capabilities ensures the most accurate and reproducible data.
CDx Assay Development
Comprehensive services for development of FDA cleared diagnostics to support therapy decisions.
Flexibility to Match Your Needs
Our team of experts can develop a customized work plan that encompasses your project’s every need, delivering information on time and on budget to help discover and validate spatial biomarkers needed to propel your research forward.
Off-the-shelf (OTS) panels or customized
Level of validation
Tiered service offering enables custom assay validation
Ability to run projects of varying scales with minimal impact on performance and turnaround time
Staged project management
Milestone-based pricing provides flexibility to meet client needs and budget
Support Across the Biomarker Development Process
Akoya offers the most advanced and complete solution for multiplexed tissue analysis. Leverage our expertise to support your tissue analysis needs.
- Assay Design, Development and Validation
- Sample Procurement
- Sample Preparation
- Pathology Review
- Tissue Staining
- Image Acquisition using Vectra Polaris scanner
Analytics and Reporting
- Image Analysis Algorithm Development and Validation
- Image Interpretation and Analysis
AstraZeneca and Akoya Collaboration
On Spatial Biology Approach to Profiling Tumor-Immune Biology
The partnership aims to leverage spatial biology data, generated on Akoya’s Phenoptics™ platform, to inform and guide drug development programs